Opendata, web and dolomites

PMSMatTrain SIGNED

Novel Biomaterial-based Device for the Treatment of Progressive MS- - An Integrated Pan- European Approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PMSMatTrain project word cloud

Explore the words cloud of the PMSMatTrain project. It provides you a very rough idea of what is the project "PMSMatTrain" about.

education    protocols    cns    cgmp    sclerosis    compulsory    manufacturing    modifying    beneficiaries    spectrophotometry    pmsmattrain    elusion    mass    cortex    industry    cultures    vivo    organotypic    commercialisation    transferable    scaled    utilise    spif    complementary    degenerative    quality    gaining    hyaluronan    scaffolds    directed    employable    miconazole    designed    stem    training    entrepreneurship    smes    intellectual    translation    model    property    policy    functionalised    esrs    remyelination    basics    stage    chronic    tool    mri    patient    pms    proximal    cell    silico    regulatory    progressive    axonal    april    inflammatory    device    demyelination    jrtp    ms    characterised    molecules    arising    affairs    multiple    biomaterials    recruited    neuroprotective    weight    dispersal    tested    first    innovation    therapy    evaluation    skills    disease    anti    small    neuroinflammation    release    talk    medical    time    signals    molecular    generate    receive    ibudilast    oligodendrocyte    clinically    drug    gender    biomimetic    cross    discipline    drugs    mechanisms    joint    followed    neuroprotection    leadership    pathophysiology    modal    standardised    immediately    yield   

Project "PMSMatTrain" data sheet

The following table provides information about the project.

Coordinator
NATIONAL UNIVERSITY OF IRELAND GALWAY 

Organization address
address: UNIVERSITY ROAD
city: Galway
postcode: H91
website: www.nuigalway.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 3˙962˙143 €
 EC max contribution 3˙962˙143 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2023-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NATIONAL UNIVERSITY OF IRELAND GALWAY IE (Galway) coordinator 1˙373˙421.00
2    UNIVERSITEIT ANTWERPEN BE (ANTWERPEN) participant 512˙640.00
3    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER DE (MUENSTER) participant 505˙576.00
4    NEOS SURGERY SL ES (DONOSTIA SAN SEBASTIAN) participant 501˙809.00
5    SYDDANSK UNIVERSITET DK (ODENSE M) participant 297˙522.00
6    UNIVERSITE GRENOBLE ALPES FR (GRENOBLE) participant 274˙802.00
7    UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA IT (CHIETI) participant 261˙499.00
8    CONTIPRO AS CZ (DOLNI DOBROUC) participant 234˙871.00
9    UNIVERSITE GRENOBLE ALPES FR (SAINT MARTIN D'HERES) participant 0.00

Map

 Project objective

PMSMatTrain is focusing on gaining a comprehensive understanding of the progressive (late degenerative phase) of multiple sclerosis (PMS) from basics to translation, fully supported by 8 beneficiaries (6 research institutions, 2 SMEs). Recruited ESRs will receive compulsory discipline-specific, generic and complementary transferable skills training. PMSMatTrain’s Joint Research Education and Training programme (JRTP) will provide early stage researchers with high quality research and transferable skills training in intellectual property, leadership skills, innovation, regulatory affairs, entrepreneurship, gender policy, and medical device evaluation, which will ensure that they are immediately employable in industry. The consortium will develop a multi-modal hyaluronan-based medical device designed to release small molecular weight anti-inflammatory molecules (APRIL and sPIF) followed by remyelination and neuroprotective drugs (ibudilast and miconazole). PMSMatTrain will for the first time utilise these functionalised multi-modal biomimetic hyaluronan scaffolds as a tool to investigate cross-talk between signals arising due to chronic neuroinflammation and those leading to demyelination and axonal loss, while identifying molecular mechanisms that facilitate remyelination and neuroprotection in PMS. This approach could yield the first cortex-proximal and directed biomaterials-based disease-modifying therapy for PMS. These scaffolds will be tested in state of the art MS patient induced stem cell-derived oligodendrocyte cultures and organotypic cultures to investigate MS pathophysiology. In vivo responses will be characterised using field-leading MRI and mass spectrophotometry protocols. PMSMatTrain will also generate a clinically-relevant in silico model of drug elusion and dispersal within the CNS. Our industry partners will develop the end-device by providing standardised manufacturing protocols for scaled-up production and commercialisation of the cGMP product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PMSMATTRAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PMSMATTRAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

HeatNMof (2020)

Heating triggered drug release from nanometric inorganic-metal organic framework composites

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More